Affiliations: [a] Laboratory of Molecular Oncology, The Rockefeller University, New York, NY 10021, USA. Tel.: +1 212 327-8805; Fax: +1 212 327-7943; E-mail: monteia@rockvax.rockefeller.edu | [b] Bristol-Myers Squibb, Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492-7660, USA
Correspondence:
[*]
Corresponding author
Abstract: Germ-line mutations in BRCA1 account for the majority of families with breast and ovarian cancer predisposition. BRCA1 encodes a 1,863 amino acid protein with no ascribed function. Due to its size and the fact that mutations are evenly scattered along the sequence, screening for mutations is particularly challenging. Here we review recently published yeast-based assays that may form the basis of an alternative diagnostic test for BRCA1. Although individually limited, these assays may, when combined, become a useful method to screen for cancer predisposing mutations. In any event, the yeast-based assays could complement results from direct sequencing providing functional information about unique mutations.
